News

Categories

October 2, 2026

Zymeworks to Present on Preclinical and Clinical Programs at Multiple Upcoming Medical Conferences

August 31, 2026

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

June 29, 2026

Zymeworks to Acquire Theravance Biopharma, Inc.

June 14, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

May 27, 2026

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

May 27, 2026

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

May 8, 2026

Zymeworks to Present at Respiratory Innovation Summit

April 29, 2026

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

April 27, 2026

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

April 21, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

April 9, 2026

Zymeworks to Present at the AACR Oncology Industry Partnering Event

November 4, 2025

Zymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference